Cardiovascular medicine is undergoing a fundamental transformation with the advent of Lepodisiran, a groundbreaking investigational drug developed by Eli Lilly that targets the genetically determined lipoprotein(a) [Lp(a)]. Elevated Lp(a) is recognized as an independent and causal risk factor for heart attack, stroke, and aortic valve stenosis, yet until now, there has been no approved therapy capable of lowering it effectively.
The pivotal Phase 2 ALPACA study demonstrated that a single injection of Lepodisiran, based on small interfering RNA (siRNA) technology, reduced plasma Lp(a) concentrations by up to 94 % over a period of 180 days, with sustained suppression for more than 12 months. The drug acts by silencing the messenger RNA responsible for apolipoprotein(a) synthesis in the liver, effectively turning off the gene that drives Lp(a) production. (Fonte)
Unlike low-density lipoprotein (LDL), which responds to diet, lifestyle, and statin therapy, Lp(a) levels are largely genetically determined and remain stable throughout life. This has made them particularly challenging to modify with conventional treatments. Lepodisiran, therefore, represents a paradigm shift: a therapy that intervenes at the genetic level to neutralize a lifelong cardiovascular risk factor.
Clinical data presented at the American Heart Association (AHA) 2025 Scientific Sessions revealed that Lepodisiran achieved profound and durable reductions in Lp(a) across diverse patient populations, with no major safety concerns observed during the study period. Researchers noted consistent effects across gender, ethnicity, and baseline lipid profiles, highlighting the broad therapeutic potential of the compound. (Fonte)
Mechanistically, the siRNA molecule in Lepodisiran uses the cell’s natural RNA interference (RNAi) pathway to bind and degrade apo(a) messenger RNA before it can produce the protein. This “gene silencing” strategy provides a highly specific and long-lasting therapeutic effect, enabling less frequent dosing compared to traditional lipid-lowering drugs. In some cases, researchers reported that a single annual dose may be sufficient to maintain low Lp(a) levels.
The implications for cardiovascular prevention are substantial. Studies have consistently shown that high Lp(a) concentrations double the risk of premature myocardial infarction and accelerate atherosclerosis, even in patients with otherwise normal cholesterol. By directly targeting the root cause, Lepodisiran could complement statins, PCSK9 inhibitors, and lifestyle measures in comprehensive cardiovascular prevention strategies.
While the Phase 3 outcome trials are ongoing, experts emphasize the need to test whether lowering Lp(a) translates into fewer cardiovascular events. Nevertheless, the data so far provide strong biological plausibility that reducing this inherited lipoprotein may finally allow clinicians to address one of the most persistent residual risks in cardiology.
In conclusion, Lepodisiran is more than an incremental improvement—it represents a new class of precision therapies designed to silence harmful genes and prevent disease before symptoms arise. If confirmed in larger trials, it could redefine preventive cardiology and help millions of people worldwide with genetically elevated lipoprotein(a) live longer, healthier lives.
Copyright © All rights reserved – Salute33